title: The effect of PTH antagonist BIM-44002 on serum calcium and PTH levels in hypercalcemic hyperparathyroid patients.
abstract: BIM-44002, a pure competitive antagonist of parathyroid hormone (PTH), has a high affinity for the PTH/PTHrP receptor in vitro, and can completely inhibit the actions of a PTH agonist in rats in vivo. Toxicology studies in rats and dogs showed BIM-44002 to be devoid of any adverse effects. Therefore we undertook an investigation to evaluate the potential utility of BIM-44002 in lowering elevated serum calcium in three patients with primary hyperparathyroidism. BIM-44002 was administered by continuous intravenous infusion at dosages of 100 microg/hour (370 nmol/hour) for 12 hours, followed by 200 microg/hour for 12 hours, followed by 400 microg/hour for 12 hours. Vital signs and serum ionized and total calcium were monitored hourly and for 3 hours after cessation of the infusion. Blood for PTH determinations was obtained at the same time points. Serum calcium and PTH did not change during and after the infusion of the antagonist. No subject experienced any adverse reactions to the infusion of the antagonist. We conclude that although the PTH antagonist BIM-44002 was effective both in vitro and in vivo in animals, and it was safe in humans, it was not able to lower serum calcium in patients with hyperparathyroidism. Possible reasons for lack of clinical efficacy are discussed.
authors.affiliation: Divisions of Bone and Mineral Metabolism, and Endocrinology, Harvard-Thorndike Laboratories of the Beth Israel Deaconess Medical Center, Department of Medicine, Beth Israel Deaconess Medical Center, Boston Massachusetts 02215, USA.
authors.forename: H N
authors.initials: HN
authors.lastname: Rosen
authors.forename: M
authors.initials: M
authors.lastname: Lim
authors.forename: J
authors.initials: J
authors.lastname: Garber
authors.forename: S
authors.initials: S
authors.lastname: Moreau
authors.forename: H N
authors.initials: HN
authors.lastname: Bhargava
authors.forename: J
authors.initials: J
authors.lastname: Pallotta
authors.forename: R
authors.initials: R
authors.lastname: Spark
authors.forename: S
authors.initials: S
authors.lastname: Greenspan
authors.forename: M
authors.initials: M
authors.lastname: Rosenblatt
authors.forename: M
authors.initials: M
authors.lastname: Chorev
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000818:Animals; D002118:Calcium / Q000097:blood*; D004285:Dogs; D005260:Female; D006801:Humans; D006934:Hypercalcemia / Q000097:blood*; D006961:Hyperparathyroidism / Q000097:blood*; D007262:Infusions, Intravenous; D007279:Injections, Subcutaneous; D008297:Male; D008875:Middle Aged; D010281:Parathyroid Hormone / Q000008:administration & dosage / Q000494:pharmacology* / Q000633:toxicity; D010446:Peptide Fragments / Q000008:administration & dosage / Q000494:pharmacology* / Q000633:toxicity; D051381:Rats; D017207:Rats, Sprague-Dawley; D018016:Receptors, Parathyroid Hormone / Q000037:antagonists & inhibitors
chemical_list: C095805:BIM 44002; D010281:Parathyroid Hormone; D010446:Peptide Fragments; D018016:Receptors, Parathyroid Hormone; D002118:Calcium